



cl1-2, 4-8, 19, 38-41, 43

TECH CENTER 1600/2800

JAN 03 2003

RECEIVED

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

Atty. Docket: EIS-SCHWARTZ=

EISENBACK-SCHWARTZ et al

Conf. No.: 4767

Appln. No.: 09/314,161

Art Unit: 1647

Filed: May 19, 1999

Examiner: S. Turner

For: ACTIVATED T-CELLS, NERVOUS
SYSTEM-SPECIFIC ANTIGENS
AND THEIR USES

Washington, D.C.

December 30, 2002

12/31/2002 HDEMESS1 00000083 09314161

02 FC:2252

200.00 OP

AMENDMENT

Honorable Commissioner for Patents
Washington, D.C. 20231

Sir:

In response to the Office Action of July 30, 2002,
petition for a two-month extension of time and payment being
attached hereto, please amend as follows:

IN THE CLAIMS

Delete claims 17, 18 and 20-37 without prejudice
toward the continuation of prosecution thereof in one or more
divisional applications.

Rewrite claim 1 in amended form as follows:

Claims 1-15, 19, and 38 have been amended as follows =

1 (Twice-amended). A method for reducing neuronal
degeneration in the central nervous system or peripheral
nervous system of an individual suffering from an injury or